Lawyer For Family Of 23-Year-Old Fatally Shot by San Bernardino Officer While Running Away Disputes Police Narrative
In the FDA's approval of Clolar, the agency noted there were no gold-standard clinical studies to show whether the drug prolonged patients' lives or improved their health. But many studies aren't getting done. And in some cases they aren't starting at all. That means many drugs that made it to market with an accelerated approval are being used — sometimes for years — without patients, doctors or regulators knowing if they really work.
NPR found that the FDA can also be lenient about deadlines for these confirmatory studies. For example, NPR identified 33 studies with anticipated completion dates that are a year or more behind their FDA due dates, accounting for about a quarter of all studies required of accelerated approval drugs that haven't yet been converted to regular approvals. However, this leaves out another 28% that are nowhere to be found in the clinical trials registry, indicating that they haven't begun.
Patients are already taking it, and some may even think it works. Though without a confirmatory trial, it's not clear. Nevertheless, she added,"the company is very happy selling it."While companies making drugs with accelerated approvals drag their feet to start confirmatory studies, they are also more likely to increase the prices of those drugs, according to GoodRx, a website that helps patients get discounts on drugs.
It can take 10 years or more to bring a new drug to market, but AIDS cases and deaths were climbing. Anderson remembers when someone he knew in the activism community died every month, prompting a funeral march each time down Los Angeles' Santa Monica Boulevard. Instead of waiting to find out whether patients taking the drug lived longer, researchers gauged the effect of the medicine on a particular kind of white blood cell that is critical for the body's immune response. HIV depletes these CD4 cells, so a medicine that improved patients' CD4 count was presumed to be beneficial.
She said that most accelerated approvals do eventually go on to be converted to regular approvals or withdrawn, and that only around 10% are still waiting for evidence after five years., however. And the agency's 2023 budget document includes legislative proposals that would give the FDA more power to solve the problem of tardy trials.
A prominent boxed warning about the limitations of data used for the accelerated approval of Invirase is no longer common. Sherman, who was working in the FDA's Center for Drug Evaluation and Research at the time, says that was her responsibility. "It's just crazy that they can have this product out there and have all that information, and it's just not really hashed out there for the public,"said Bonds."Because if you just go on [Makena's] website, there's just big quotes and words about it working and how great it is and the benefits about it."
The Bonds' baby was born on a stretcher on the side of the road between their car and the ambulance. He weighed 3 pounds, 9 ounces. Named Phoenix, the preemie would spend the next 83 days in the neonatal intensive care unit and still has health issues. Makena is one of 13 drugs that got accelerated approvals and whose confirmatory studies were finished more than a year ago yet still haven't been either converted to a regular approval or taken off the market by FDA, an NPR analysis found. Some of these drugs have had completed studies for six, seven or even 22 years. Yet they're still in limbo.For the first two decades that accelerated approval was an option, the FDA granted only a few each year.
इंडिया ताज़ा खबर, इंडिया मुख्य बातें
Similar News:आप इससे मिलती-जुलती खबरें भी पढ़ सकते हैं जिन्हें हमने अन्य समाचार स्रोतों से एकत्र किया है।
स्रोत: KPBSnews - 🏆 240. / 63 और पढो »
स्रोत: Utoday_en - 🏆 295. / 63 और पढो »
Fiat's Sleek Fastback Coupe Is Finally Getting Ready To Hit The Market | CarscoopsFiat's Sleek Fastback Coupe Is Finally Getting Ready To Hit The Market | Carscoops carscoops
स्रोत: Carscoop - 🏆 306. / 63 और पढो »